Trial reportWorld journal of gastroenterology2025
Efficacy and safety of triple therapy with vonoprazan for
Trial report in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- Potassium-Competitive Acid Blockers for First-LineGastro hep advances · 2026Review
- Real-world effectiveness of vonoprazan-based regimen versus rabeprazole-based dual therapy forFrontiers in medicine · 2026Article
- Additional considerations on vonoprazan triple therapy forWorld journal of gastroenterology · 2025Article
- Breaking barriers in the first-lineWorld journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
aimTo investigate the efficacy and safety of a vonoprazan (VPZ)-based triple regimen for first-line eradication of
methodsThis multicenter noninferior randomized controlled trial (June 2022 to November 2023) involved 524
resultsA total of 524 patients participated in this study. In ITT analysis, the eradication rates of the EBAC, VACa, and VACb groups were 72.6% (127/175), 88.0% (154/175), and 83.3% (145/174), respectively (
conclusionVPZ-based triple therapies demonstrate noninferiority to 14-day bismuth-containing regimens, with the 10-day regimen showing comparable efficacy and similar adverse event rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.